Equity Distribution Agreements in the Pharmaceuticals Industry

35 Contracts & Agreements

Browse by Company

ACHILLION PHARMACEUTICALS INC (1 contract)
Acreage Holdings, Inc. (1)
Ampio Pharmaceuticals, Inc. (1)
Anacor Pharmaceuticals, Inc. (2)
APRICUS BIOSCIENCES, INC. (1)
Aquestive Therapeutics, Inc. (1)
ARTELO BIOSCIENCES, INC. (1)
ARVINAS, INC. (1)
Biohaven Ltd. (1)
Clever Leaves Holdings Inc. (1)
Cocrystal Pharma, Inc. (4)
Eloxx Pharmaceuticals, Inc. (1)
Fulcrum Therapeutics, Inc. (1)
KEMPHARM, INC (1)
Lexaria Bioscience Corp. (1)
Lotus Pharmaceuticals, Inc. (1)
MARINUS PHARMACEUTICALS INC (2)
Novan, Inc. (1)
Onconova Therapeutics, Inc. (1)
ORAMED PHARMACEUTICALS INC. (6)
Processa Pharmaceuticals, Inc. (1)
Textmunication Holdings, Inc. (1)
TITAN PHARMACEUTICALS INC (1)
VIVUS INC (1)
ZOGENIX, INC. (1)

Recent Contracts

Equity Distribution Agreement, dated as of October 2, 2023, by and between Biohaven Ltd. and J.P. Morgan Securities LLC (Biohaven Ltd., Filed With SEC on October 3, 2023)
Amendment No. 1 to the Equity Distribution Agreement, dated as of March 31, 2023, by and between Marinus Pharmaceuticals, Inc. and JMP Securities LLC (MARINUS PHARMACEUTICALS INC, Filed With SEC on March 31, 2023)
Equity distribution agreement, dated as of August 12, 2022 (Lexaria Bioscience Corp., Filed With SEC on August 12, 2022)
Equity Distribution Agreement, dated May 9, 2022, by and between the Company and Piper Sandler & Co (Fulcrum Therapeutics, Inc., Filed With SEC on May 10, 2022)
Equity Distribution Agreement, dated (Novan, Inc., Filed With SEC on March 11, 2022)
Equity Distribution Agreement, dated January 14, 2022, by and between Clever Leaves Holdings Inc. and Canaccord Genuity LLC (Clever Leaves Holdings Inc., Filed With SEC on January 14, 2022)
Equity Distribution Agreement, dated September 1, 2021, by and between the Company and Cantor Fitzgerald & Co (ORAMED PHARMACEUTICALS INC., Filed With SEC on September 1, 2021)
Equity Distribution Agreement, dated August 20, 2021, by and among Processa Pharmaceuticals, Inc. and Oppenheimer & Co. Inc (Processa Pharmaceuticals, Inc., Filed With SEC on August 20, 2021)
Equity Distribution Agreement, dated as of August 20, 2021, between Onconova Therapeutics, Inc. and Piper Sandler & Co (Onconova Therapeutics, Inc., Filed With SEC on August 20, 2021)
Equity Distribution Agreement, dated August 6, 2021, by and among Arvinas, Inc., Piper Sandler & Co. and Cantor Fitzgerald & Co (ARVINAS, INC., Filed With SEC on August 6, 2021)
Equity Distribution Agreement, dated July 15, 2021, by and between the Company and Canaccord Genuity (ORAMED PHARMACEUTICALS INC., Filed With SEC on July 15, 2021)
Equity Distribution Agreement, dated July 2, 2021, by and among KemPharm, Inc., JMP Securities LLC and RBC Capital Markets, LLC (KEMPHARM, INC, Filed With SEC on July 2, 2021)
Equity Distribution Agreement, dated June 16, 2021, by and between the Company and Canaccord Genuity (ORAMED PHARMACEUTICALS INC., Filed With SEC on June 16, 2021)
Letter amending the Standby Equity Distribution Agreement by and between the Institutional Investor and Acreage Holdings, Inc., dated March 11, 2021 (Acreage Holdings, Inc., Filed With SEC on March 26, 2021)
Amendment No. 1 to the Equity Distribution Agreement, dated March 26, 2021, by and between Aquestive Therapeutics, Inc. and Piper Sandler & Co (Aquestive Therapeutics, Inc., Filed With SEC on March 26, 2021)
Equity Distribution Agreement, dated December 1, 2020, by and between the Company and Canaccord Genuity (ORAMED PHARMACEUTICALS INC., Filed With SEC on December 1, 2020)
Equity Distribution Agreement by and among the Company and Maxim Group LLC dated as of April 13, 2020 (ARTELO BIOSCIENCES, INC., Filed With SEC on April 15, 2020)
Amendment to the Equity Distribution Agreement, dated February 10, 2020, between Canaccord Genuity LLC and Oramed Pharmaceuticals Inc (ORAMED PHARMACEUTICALS INC., Filed With SEC on April 6, 2020)
Equity Distribution Agreement, dated as of March 6, 2020, between VIVUS, Inc. and Piper Sandler & Co (VIVUS INC, Filed With SEC on March 6, 2020)
Amendment to the Amended and Restated Equity Distribution Agreement, dated October 2, 2019 (Cocrystal Pharma, Inc., Filed With SEC on January 29, 2020)
Amended and Restated Equity Distribution Agreement, dated October 30, 2019 (Cocrystal Pharma, Inc., Filed With SEC on October 30, 2019)
Equity Distribution Agreement, dated September 5, 2019, by and between the Company and Canaccord Genuity (ORAMED PHARMACEUTICALS INC., Filed With SEC on September 5, 2019)
Equity Distribution Agreement, dated as of June 17, 2019, by and between Seelos Therapeutics, Inc. and Piper Jaffray & Co (APRICUS BIOSCIENCES, INC., Filed With SEC on June 18, 2019)
Equity Distribution Agreement, dated as of April 12, 2019, by and between Canaccord Genuity LLC and Ampio Pharmaceuticals, Inc (Ampio Pharmaceuticals, Inc., Filed With SEC on April 15, 2019)
Amendment to Equity Distribution Agreement, dated March 20, 2019 (Cocrystal Pharma, Inc., Filed With SEC on March 26, 2019)
Equity Distribution Agreement, dated November 16, 2018, by and between Eloxx Pharmaceuticals, Inc., Citigroup Global Markets Inc. and Cantor Fitzgerald & Co (Eloxx Pharmaceuticals, Inc., Filed With SEC on November 16, 2018)
Equity Distribution Agreement, dated July 19, 2018 (Cocrystal Pharma, Inc., Filed With SEC on July 20, 2018)
Equity Distribution Agreement dated as of October 31, 2017 between the Company and JMP Securities LLC (MARINUS PHARMACEUTICALS INC, Filed With SEC on October 31, 2017)
STANDBY EQUITY DISTRIBUTION AGREEMENT (SEDA) (Textmunication Holdings, Inc., Filed With SEC on June 6, 2014)
ANACOR PHARMACEUTICALS, INC. AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT (Anacor Pharmaceuticals, Inc., Filed With SEC on March 18, 2013)
ANACOR PHARMACEUTICALS, INC. EQUITY DISTRIBUTION AGREEMENT (Anacor Pharmaceuticals, Inc., Filed With SEC on March 18, 2013)
McKesson Corporation Strategic Redistribution Center and Core Distribution Agreement (ZOGENIX, INC., Filed With SEC on September 3, 2010)
Standby Equity Distribution Agreement, dated as of March 3, 2010, by and between Lotus Pharmaceuticals, Inc. and YA Global Master SPV Ltd (Lotus Pharmaceuticals, Inc., Filed With SEC on March 5, 2010)
STANDBY EQUITY DISTRIBUTION AGREEMENT (ACHILLION PHARMACEUTICALS INC, Filed With SEC on July 6, 2009)
STANDBY EQUITY DISTRIBUTION AGREEMENT (TITAN PHARMACEUTICALS INC, Filed With SEC on September 30, 2005)